Messenger RNA-Based Flu Vaccine Makes Its Debut in U.S. Pharmacies: Who Can Get It?
Article excerpt
Highlighted: the sentence this signal was extracted from
The novel flu vaccine formulated with messenger RNA (mRNA) technology has officially arrived at pharmacies across the United States. Moderna's mFlusiva is now available nationwide at CVS pharmacies, while Walgreens is gearing up to receive shipments imminently. On August 6, the Food and Drug Administration (FDA) gave the green light to mFlusiva for individuals aged 50 and above, paving the way for its availability ahead of the flu season. So, who qualifies for the mFlusiva vaccination? According to the FDA's authorization, mFlusiva is intended strictly for adults aged 50 and over. The agency provided standard approval for those between 50 to 64 years and an accelerated approval for individuals 65 years or older, contingent on an additional clinical trial for this age bracket. Individuals outside this age range can opt for other approved flu vaccines suitable for their demographic. Unlike traditional flu vaccines - which typically use inactivated virus versions cultivated in eggs - mFlusiva utilizes a small piece of genetic code to train the immune system to recognize and combat the virus. "Think of it as a temporary instruction for your immune system to alert your body's natural defenses to identify the flu," explained Emlah Tubuo, an independent pharmacist based in Ohio, to NBC News. The mRNA disintegrates once its job is done, leaving no residue in the body. Immunity...
Keep reading with a free account
The rest of this article, and every signal for Moderna, is in your free account.
